Literature DB >> 17876721

The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).

A R Garcia1, J Pan, J C Lamsa, J Muenzer.   

Abstract

Mucopolysaccharidosis II (MPS II, Hunter syndrome in humans) is an X-linked inherited lysosomal storage disease caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase (I2S). I2S catalyses a step in the catabolism of glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, and when it is deficient or absent GAGs accumulate in tissues and organs. Male knockout mice (IdS-KO), which lack the gene coding for I2S, exhibit many of the characteristics seen in the human disease. Compared to wild-type control mice, urine GAG excretion was elevated at 4 weeks of age and remained high throughout the lifespan, and tissue GAG levels were elevated as early as 7 weeks of age. Liver, spleen and other organs were significantly larger in the IdS-KO mice than in the wild-type. Radiographic examination revealed sclerosis and enlargement of the skull at 4 weeks of age and appendicular bone enlargement at 10-13 weeks of age. Micro CT scans showed severe periosteal bone formation at the lateral aspect of the distal tibia and calcification of the calcaneus tendon. This model was used in the development of idursulfase for treatment of MPS II and may continue to be useful in the evaluation of treatment strategies of this chronic and progressive disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876721     DOI: 10.1007/s10545-007-0641-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.

Authors:  Adelaide Friso; Rosella Tomanin; Sabrina Alba; Nicoletta Gasparotto; Elisabetta Piller Puicher; Mariella Fusco; Gonzalo Hortelano; Joseph Muenzer; Oriano Marin; Franco Zacchello; Maurizio Scarpa
Journal:  J Gene Med       Date:  2005-11       Impact factor: 4.565

2.  Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue.

Authors:  J G de Jong; R A Wevers; R Liebrand-van Sambeek
Journal:  Clin Chem       Date:  1992-06       Impact factor: 8.327

3.  Enzyme replacement therapy in feline mucopolysaccharidosis I.

Authors:  E D Kakkis; E Schuchman; X He; Q Wan; S Kania; S Wiemelt; C W Hasson; T O'Malley; M A Weil; G A Aguirre; D E Brown; M E Haskins
Journal:  Mol Genet Metab       Date:  2001-03       Impact factor: 4.797

4.  Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI.

Authors:  M Evers; P Saftig; P Schmidt; A Hafner; D B McLoghlin; W Schmahl; B Hess; K von Figura; C Peters
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

5.  Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses.

Authors:  J G de Jong; R A Wevers; C Laarakkers; B J Poorthuis
Journal:  Clin Chem       Date:  1989-07       Impact factor: 8.327

6.  A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease).

Authors:  Y V Voznyi; J L Keulemans; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

7.  Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.

Authors:  E H Birkenmeier; M T Davisson; W G Beamer; R E Ganschow; C A Vogler; B Gwynn; K A Lyford; L M Maltais; C J Wawrzyniak
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

8.  Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.

Authors:  L A Clarke; C S Russell; S Pownall; C L Warrington; A Borowski; J E Dimmick; J Toone; F R Jirik
Journal:  Hum Mol Genet       Date:  1997-04       Impact factor: 6.150

9.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).

Authors:  Joseph Muenzer; James E Wraith; Michael Beck; Roberto Giugliani; Paul Harmatz; Christine M Eng; Ashok Vellodi; Rick Martin; Uma Ramaswami; Muge Gucsavas-Calikoglu; Suresh Vijayaraghavan; Susanne Wendt; Suzanne Wendt; Ana Cristina Puga; Antonio Puga; Brian Ulbrich; Marwan Shinawi; Maureen Cleary; Diane Piper; Anne Marie Conway; Ann Marie Conway; Alan Kimura
Journal:  Genet Med       Date:  2006-08       Impact factor: 8.822

10.  Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.

Authors:  Monica Cardone; Vinicia Assunta Polito; Stefano Pepe; Linda Mann; Alessandra D'Azzo; Alberto Auricchio; Andrea Ballabio; Maria Pia Cosma
Journal:  Hum Mol Genet       Date:  2006-02-27       Impact factor: 6.150

View more
  25 in total

1.  Mechanism of shortened bones in mucopolysaccharidosis VII.

Authors:  Jason A Metcalf; Yanming Zhang; Matthew J Hilton; Fanxin Long; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2009-03-25       Impact factor: 4.797

2.  Aversive and non-aversive memory impairment in the mucopolysaccharidosis II mouse model.

Authors:  Amanda Stapenhorst Azambuja; Lilian Correa; Bernardo Pappi Gabiatti; Giselle Renata Martins; Álvaro de Oliveira Franco; Maria Flávia Marques Ribeiro; Guilherme Baldo
Journal:  Metab Brain Dis       Date:  2017-09-16       Impact factor: 3.584

3.  Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.

Authors:  Daniel J Rowan; Shunji Tomatsu; Jeffrey H Grubb; Adriana M Montaño; William S Sly
Journal:  J Inherit Metab Dis       Date:  2012-09-13       Impact factor: 4.982

4.  The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.

Authors:  Young Bae Sohn; Ah-Ra Ko; Mi-Ran Seong; Soyeon Lee; Mi Ra Kim; Sung Yoon Cho; Jung-Sun Kim; Makoto Sakaguchi; Takahiro Nakazawa; Motomichi Kosuga; Joo Hyun Seo; Torayuki Okuyama; Dong-Kyu Jin
Journal:  J Inherit Metab Dis       Date:  2018-07-05       Impact factor: 4.982

5.  Effect of donor chimerism to reduce the level of glycosaminoglycans following bone marrow transplantation in a murine model of mucopolysaccharidosis type II.

Authors:  Kentaro Yokoi; Kazumasa Akiyama; Eiko Kaneshiro; Takashi Higuchi; Yohta Shimada; Hiroshi Kobayashi; Masaharu Akiyama; Makoto Otsu; Hiromitsu Nakauchi; Toya Ohashi; Hiroyuki Ida
Journal:  J Inherit Metab Dis       Date:  2014-12-13       Impact factor: 4.982

6.  Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model.

Authors:  Daniel J Rowan; Shunji Tomatsu; Jeffrey H Grubb; Bisong Haupt; Adriana M Montaño; Hirotaka Oikawa; Angela C Sosa; Anping Chen; William S Sly
Journal:  Mol Genet Metab       Date:  2012-07-14       Impact factor: 4.797

7.  Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

Authors:  Ramin Sedaghat Herati; Van W Knox; Patricia O'Donnell; Marina D'Angelo; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

8.  Analysis of male reproductive parameters in a murine model of mucopolysaccharidosis type I (MPS I).

Authors:  Cinthia Castro do Nascimento; Odair Aguiar Junior; Vânia D'Almeida
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.

Authors:  Roselena Silvestri Schuh; Esteban Alberto Gonzalez; Angela Maria Vicente Tavares; Bruna Gazzi Seolin; Lais de Souza Elias; Luisa Natalia Pimentel Vera; Francyne Kubaski; Edina Poletto; Roberto Giugliani; Helder Ferreira Teixeira; Ursula Matte; Guilherme Baldo
Journal:  Gene Ther       Date:  2019-12-11       Impact factor: 5.250

10.  Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.

Authors:  T Andrew Burrow; Nancy D Leslie
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.